利格列汀聯(lián)合二甲雙胍治療2型糖尿病療效分析
發(fā)布時間:2018-06-24 來源: 日記大全 點擊:
[摘要] 目的 探究臨床治療2型糖尿病患者的過程中,應用利格列汀與二甲雙胍聯(lián)合治療的臨床價值,為臨床糖尿病的治療奠定基礎。方法 自該院2016年1月—2017年3月期間收治的2型糖尿病患者,隨機抽取60例并予以分組治療,2組均給予基礎治療,包括飲食治療、運動方式。在此基礎上,對照組30例患者加用二甲雙胍治療,試驗組30例患者加用利格列汀與二甲雙胍聯(lián)合治療,對比兩組療效及血糖水平。結果 予以不同治療方案后,試驗組臨床總有效率(90.0%,27/30)顯著高于對照組(73.3%,22/30),差異有統(tǒng)計學意義(P<0.01)。試驗組患者的FBG(5.8±0.4)mmol/L、PBG(8.31±0.6)mmol/L、HbA1c(6.41±0.1)%、BMI(70.1±28.1)kg/m2各項血糖參數(shù)改善幅度均顯著優(yōu)于對照組(7.12±0.3)mmol/L、(9.29±0.3)mmol/L、(7.31±0.8)%、(60.0±6.9)kg/m2,差異有統(tǒng)計學意義(P<0.05)。結論 臨床治療2型糖尿病患者的過程中,應用利格列汀與二甲雙胍片聯(lián)合治療可顯著穩(wěn)定患者的血糖,并有助于治療效果的提升,應廣泛推廣。
[關鍵詞] 2型糖尿;利格列汀;二甲雙胍;療效
[中圖分類號] R5 [文獻標識碼] A [文章編號] 1674-0742(2018)01(c)-0118-03
[Abstract] Objective This paper tries to explore the clinical treatment of patients with type 2 diabetes, the clinical application value of pioglitazone and metformin, to lay the foundation for clinical treatment of diabetes mellitus. Methods 60 patients in this hospital from January 2016 to March 2017 with type 2 diabetic were randomly selected and divided into two groups, both groups were given basic treatment, including diet therapy, exercise mode. On this basis, the control group of 30 patients treated with metformin, 30 patients in the test group treated with pioglitazone and metformin treatment, compared two groups of curative effect and blood glucose levels. Results After adopting different treatment methods, the total effective rate of treatment group (90.0%,27/30) significantly higher than that of the control group (73.3%,22/30), with significant difference(P<0.01). Patients in the experimental group of FBG(5.8±0.4)mmol/L, PBG (8.31±0.6)mmol/L, HbA1c(6.41±0.1)%, BMI (70.1±28.1)kg/m2, parameters of blood glucose improvement were significantly better than those of the control group[(7.12±0.3)mmol/L,(9.29±0.3)mmol/L,(7.31±0.8)%,(60.0±6.9)kg/m2], the difference was significant(P<0.05). Conclusion The clinical treatment of patients with type 2 diabetes, the combination of pioglitazone and metformin enteric coated tablets can significantly stabilize the blood glucose of patients, and help to improve the treatment effect, which should be widely promoted.
[Key words] Type 2 diabetes mellitus; Pioglitazone; Metformin; Efficacy
作為臨床慢性病常見類型之一的糖尿病,其發(fā)病率呈逐年升高趨勢。其中,以2型糖尿病的發(fā)病率更高,發(fā)病機制多數(shù)是因胰島素作用障礙或胰島素分泌缺陷導致,并以血糖異常升高為臨床特征,并具有“三多一少”的典型癥狀[1]。隨著人民生活水平和生活方式的改變,2型糖尿病的發(fā)病率逐年升高,調查顯示,我國20歲以上人群2型糖尿病的發(fā)病率達9.7%。如可以保證血糖控制在正常范圍內,則有利于患者生活質量的保證,并推遲并發(fā)癥的衍生[2]。多項研究顯示,非健康的生活方式可加重糖尿病的病情,并誘發(fā)其他嚴重的并發(fā)癥。為此,該研究隨機選擇該院2016年1月—2017年3月期間收治的2型糖尿病患者60例為研究對象,旨在探究應用利格列汀與二甲雙胍聯(lián)合治療2型糖尿病患者的臨床效果,為臨床糖尿病治療奠定基礎,以下是詳細報道。
熱點文章閱讀